October 2007

NEJM Takes Shots at CROs

Wednesday, October 31, 2007

A recent New England Journal of Medicine (NEJM) Perspective piece criticized the clinical trials industry for its reliance on contract research organizations (CROs). The piece describes the rapid growth in the CRO industry, questions the quality of research data it generates and cites various clinical trials that have shed some negative light on CRO-run studies.

[Read More]

Centocor Psoriasis Drug Shows Impressive Results

Monday, October 29, 2007

Johnson & Johnson’s Centocor reported positive results from a phase III trial of CNTO1275 (ustekinumab) for the treatment of psoriasis. CNTO1275 is a monoclonal antibody (mAb) against the p40 subunit of interleukin 12 (IL-12) and IL-23. This randomized, double-blind, placebo-controlled study, dubbed PHOENIX 2, enrolled 1,230 subjects with chronic psoriasis.

[Read More]

OmniComm Inked 10 New Contracts

Friday, October 19, 2007

Florida-based electronic data capture (EDC) provider OmniComm Systems inked 10 new contracts during the third quarter of 2007. The additional deals bring the company’s total contracts to 35 for the year.

[Read More]

Gene Therapy Drug Shows Promise in MS Patients

Monday, October 15, 2007

Palo Alto, Calif.-based Bayhill Therapeutics reported positive results from a phase IIb trial of BHT-3009 for the treatment of multiple sclerosis. BHT-3009 is a gene therapy drug that delivers DNA that instructs cells to produce myelin basic protein (MBP). Myelin is the phospholipid sheath that surrounds neurons and is the target of many autoimmune diseases such as MS.

[Read More]